Lanreotide injection - Cipla
Latest Information Update: 17 Dec 2025
At a glance
- Originator Cipla
- Class Antineoplastics; Cyclic peptides; Eye disorder therapies; Pancreatic hormones; Pituitary hormone release inhibiting hormones; Urologics; Vascular disorder therapies
- Mechanism of Action Growth hormone-releasing hormone inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Acromegaly; Neuroendocrine tumours
Most Recent Events
- 17 Dec 2025 Launched for Acromegaly(Treatment-experienced, In adults) in USA (SC), prior to December 2025 (Cipla website, December 2025)
- 17 Dec 2025 Launched for Neuroendocrine tumours (Metastatic disease, Inoperable/Unresectable, Late-stage disease, In adults) in USA (SC), prior to December 2025 (Cipla website, December 2025)
- 19 Dec 2021 Registered for Acromegaly(Treatment-experienced) in USA (SC)